This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing "retained products of conception" in women, suggest findings published January 13 in the American Journal of Emergency Medicine. A team led by Zachary Boivin, MD, from Yale University in New Haven, CT, found that POCUS can accurately diagnose this tissue in patients being managed surgically or medically.
Those proposing breast imaging-related measures so far in 2025 have included Connecticut, Florida, Hawaii, Indiana, Missouri, New York, South Carolina, Utah and Virginia, ACR reports.
Researchers have designed process that uses ultrasound to modify the behavior of cancer-fighting T cells by increasing their cell permeability. They targeted freshly isolated human immune cells with tightly focused ultrasound beams and clinically approved contrast agent microbubbles. When hit with the ultrasound, the bubbles vibrate at extremely high frequency, acting as a push-pull on the walls of the T cell's membranes.
Amidst rising cancer prevalence and soaring costs, new cancer technologies and innovations are emerging to support the early detection, treatment, and surveillance of cancer. Read this guide to understand how to evaluate these solutions for your employees and members – and to learn more about the current state of coverage, clinical and cost effectiveness, and impact on quality and outcomes.
Gallium-68 (Ga-68) fibroblast activation protein inhibitor (FAPI) PET/CT is a promising new method for imaging gastric cancer, according to a study published January 16 in the Journal of Cancer Research and Clinical Oncology. The finding is from an analysis of 112 patients, with FAPI-PET scans revealing new findings in 24 patients after initial contrast-enhanced CT scans, noted a group led by Hongfeng Gou, MD, of Sichuan University in Sichuan, China.
Gallium-68 (Ga-68) fibroblast activation protein inhibitor (FAPI) PET/CT is a promising new method for imaging gastric cancer, according to a study published January 16 in the Journal of Cancer Research and Clinical Oncology. The finding is from an analysis of 112 patients, with FAPI-PET scans revealing new findings in 24 patients after initial contrast-enhanced CT scans, noted a group led by Hongfeng Gou, MD, of Sichuan University in Sichuan, China.
The less invasive method could help men avoid some of the unpleasant side effects such as urinary incontinence and sexual dysfunction, which are known deterrents for patients facing potential prostatectomy.
Concerns stem from manufacturing and distribution of the BioZorb marker, with possible ramifications including "seizure, injunction and civil money penalties.
Patient-centric scheduling can only be achieved through optimized radiology workflows, effective communications between staff and physicians, and, of course, through specialized schedulers. In this guide, we’ll take you through a step-by-step process to transform your radiology center into a high-performance hub of medical imaging.
Simulated contrast-enhanced MR images from noncontrast sequences using deep learning show promise for assessing clinically significant prostate cancer, according to a study published January 14 in Radiology. The findings could mitigate patients' exposure to contrast, wrote a team led by Hongyan Huang, MD, of Shenzhen University in China. "In [our] study, we demonstrated the feasibility of simulating contrast-enhanced images from noncontrast prostate MRI sequences," the group noted.
Indiana University radiologists explore how 1 organization lost 80% of its sonographers in a month, detailing 3 ways peers can avoid such a situation in their own organizations.
Mammography remains one of the most critical areas of radiology practice, and one that is facing changes in reporting requirements and reimbursement policy. Even with additional mammography reporting requirements placed on radiology practices, the reimbursement value of mammography services has not changed to reflect the extra work. However, changes to screening policy could provide increased mammography volume.
About 40% of us will be diagnosed with cancer in our lifetime, and patients are getting younger. At the same time, the cost of treatment continues to rise, with employers spending 8.5% more on cancer care for each employee than they did last year. The best thing employers can do for their employees and business tomorrow is to invest in cancer detection and care today.
Some CPT billing code descriptions leave ambiguity as to the number of image views involved in an exam, resulting in variability in interpretation times.
Contrast-enhanced mammography (CEM) has a slightly higher mean glandular dose (MGD) than other breast imaging modalities, according to research published January 15 in the American Journal of Roentgenology. A team led by Jeremiah Sanders, PhD, from the Mayo Clinic in Phoenix, AZ, found that MGD per breast was higher for CEM than for full-field digital mammography or digital breast tomosynthesis (DBT) alone.
Synthetic images are often of diagnostic quality and can be reliably used to assess clinically significant prostate cancer while also sparing patients from contrast exposure.
Discover how Color's comprehensive care solution is revolutionizing cancer screening adherence and knowledge. Through an in-depth case study, Color's unique approach to comprehensive cancer care has shown significant benefits in increasing screening rates and enhancing patient knowledge. Participants reported a 2-3x increase in adherence to screening guidelines over just 8 weeks, with 84% of participants increasing their familiarity with timing and frequency of cancer screening.
In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Valencia, CA-based radioisotope development company Nusano has launched commercial operations and announced a lutetium-177 (Lu-177) supply agreement with Australian targeted radiotherapy company GlyTherix. The agreement provides GlyTherix access to Nusanos future actinium-225 (Ac-225) production, currently scheduled to begin in 2026, and planned future production of zirconium-89, lead-212, and terbium-161, Nusano said.
Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time patients wait.
The University of California, San Francisco (UCSF) and GE HealthCare (GEHC) have launched a joint research hub focused on neurodegenerative disease and cancer. The Care Innovation Hub will be run under the UCSF's Department of Radiology and Biomedical Imaging, it said. The program will combine UCSFs advanced clinical and research teams with GE HealthCares technical and engineering expertise to increase the accessibility of imaging and drive new clinical techniques to diagnose and treat these cri
Explore the latest insights from the American Cancer Society's “Cancer Statistics 2024” report, which unveils multiple alarming trends in cancer data. Cancer is on the rise among young adults, and diagnoses for 6 of the 10 most common cancers are escalating. With over 2 million new cancer cases projected in the U.S. this year, employers face increased challenges when it comes to supporting employees.
More and more healthcare facilities are choosing to create a hybrid catheterization lab, which combines the traditional diagnostic functions of a Cath lab with surgical functions of a standard operating room.
The U.S. Food and Drug Administration (FDA) has issued a warning letter to specialty CT manufacturer Xoran Technologies for violations related to its xCAT IQ, xCAT XL, MiniCAT 2020, and MiniCAT IQ devices. The FDA said that design modifications to the companys xCAT IQ and xCAT XL CT scanners need to be addressed in a special 510(k) submission to ascertain their impact on safety and effectiveness, according to a letter posted January 14.
In the first part of a two-part interview, Nina Kottler, M.D. offers insights and perspective on the recently issued guidance from the FDA on AI-enabled devices and how it may impact developers in the radiology field.
Employee expectations constantly evolve as companies adjust to new technologies and shifting office dynamics. Understanding how company expectations from employees will likely change in 2025 should make it easier for executives to attract top talent. Below, you’ll learn more about some 2025 trends that will influence what a “good job” looks like in the near future.
As HR and Benefits leaders are in the midst of evaluating cancer care solutions and designing their requirements for vendors, it’s key to know what questions to ask to ensure the development of a truly comprehensive strategy: from prevention to diagnosis to treatment to survivorship. Getting to the right answers starts with asking the right questions: How can better access improve engagement?
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content